Download pdf
Mecp2: An Important Role in the Pathogenesis of RETT Syndrome
- 1 Department of Biotechnology, Qilu University of Technology, Shandong, 250353, China
* Author to whom correspondence should be addressed.
Abstract
RETT syndrome is an X-chromosome-linked neurodevelopmental disorder mainly affecting female children, and its pathogenesis is mainly related to mutations in the Mecp2. In recent years, the role of Mecp2 in neurodevelopment and its relationship with RETT syndrome has become a hot research topic. Current research is focused on the effects of Mecp2 mutations on neuronal function and neural circuits, as well as exploring potential therapeutic approaches in animal models. Despite the results achieved, there are still gaps in the understanding of the precise molecular mechanisms of the Mecp2, gender specificity and the role of non-coding RNAs. This paper analyzed the role of Mecp2 in neurodevelopment and its relationship with Rett syndrome, and explored the molecular mechanisms and potential therapeutic strategies for Mecp2 mutations. It was found that Mecp2 mutations lead to neurological dysfunction by affecting neuronal differentiation and synaptic plasticity. In addition, this paper evaluates the current prospects for gene therapy, noting that adeno-associated viral vectors (AAV) have shown favorable therapeutic effects in animal experiments. This paper provides new insights into understanding the pathogenic mechanism of the Mecp2 in RETT syndrome and provides an important reference for future therapeutic strategies. However, the precise molecular mechanism of the Mecp2 and its gender-specific differences still need further investigation. Future studies could focus on developing safer and more effective gene therapies and exploring the role of non-coding RNAs in RETT syndrome with a view to achieving more comprehensive therapeutic strategies
Keywords
Mecp2, RETT Syndrome, Neurodevelopmental Disorder, Epigenetics
[1]. Pejhan, S., & Rastegar, M. (2021). Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease. Biomolecules, 11(1), 75. https://doi.org/10.3390/biom11010075.
[2]. Sharifi, O., & Yasui, D. H. (2021). The Molecular Functions of MeCP2 in Rett Syndrome Pathology. Front Genet, 12, 624290. https://doi.org/10.3389/fgene.2021.624290.
[3]. Liyanage V R B, Rastegar M. (2014). Rett syndrome and MeCP2. Neuromolecular medicine. 16: 231-264.
[4]. Ramocki M B, Tavyev Y J, Peters S U. (2010). The MECP2 duplication syndrome. American journal of medical genetics Part A. 152(5): 1079-1088.
[5]. Li, M. R., Pan, H., Bao, X. H., Zhang, Y. Z., Jiang, S. L., & Wu, X. R. (2006). Zhonghua Er Ke Za Zhi, 44(4), 285-288.
[6]. Khrapunov, S., Warren, C., Cheng, H., Berko, E. R., Greally, J. M., & Brenowitz, M. (2014). Unusual characteristics of the DNA binding domain of epigenetic regulatory protein MeCP2 determine its binding specificity. Biochemistry, 53(21), 3379-3391. https://doi.org/10.1021/bi500424z.
[7]. Chen, Y., Wu, X. L., Hu, H. B., et al. (2023). Neuronal MeCP2 in the dentate gyrus regulates mossy fiber sprouting of mice with temporal lobe epilepsy. Neurobiol Dis, 188, 106346. https://doi.org/10.1016/j.nbd.2023.106346.
[8]. Boxer, L. D., Renthal, W., Greben, A. W., et al. (2020). MeCP2 represses the rate of transcriptional initiation of highly methylated long genes. Mol Cell, 77(2), 294-309.e9. https://doi.org/10.1016/j.molcel.2019.10.032.
[9]. Kyle, S. M., Vashi, N., & Justice, M. J. (2018). Rett syndrome: a neurological disorder with metabolic components. Open Biol, 8(2), 170216. https://doi.org/10.1098/rsob.170216.
[10]. Good, K. V., Vincent, J. B., & Ausió, J. (2021). MeCP2: The genetic driver of Rett syndrome epigenetics. Front Genet, 12, 620859. https://doi.org/10.3389/fgene.2021.620859.
[11]. Collins, B. E., & Neul, J. L. (2022). Rett Syndrome and MECP2 Duplication Syndrome: Disorders of MeCP2 Dosage. Neuropsychiatr Dis Treat, 18, 2813-2835. https://doi.org/10.2147/NDT.S371483.
[12]. Newnham, C. M., Hall-Pogar, T., Liang, S., et al. (2010). Alternative polyadenylation of MeCP2: Influence of cis-acting elements and trans-acting factors. RNA Biol, 7(3), 361-372. https://doi.org/10.4161/rna.7.3.11564.
[13]. Pejhan, S., & Rastegar, M. (2021). Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease. Biomolecules, 11(1), 75. https://doi.org/10.3390/biom11010075.
[14]. He, X. B., Guo, F., Li, K., Yan, J., & Lee, S. H. (2022). Timing of MeCP2 expression determines midbrain dopamine neuron phenotype specification. Stem Cells, 40(11), 1043-1055. https://doi.org/10.1093/stmcls/sxac061.
[15]. Sinnett, S. E., Boyle, E., Lyons, C., & Gray, S. J. (2021). Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice. Brain, 144(10), 3005-3019. https://doi.org/10.1093/brain/awab182.
[16]. Sun, N., Yu, L., Gao, Y., et al. (2021). MeCP2 epigenetic silencing of Oprm1 gene in primary sensory neurons under neuropathic pain conditions. Front Neurosci, 15, 743207. https://doi.org/10.3389/fnins.2021.743207.
[17]. Vilvarajan, S., McDonald, M., Douglas, L., et al. (2023). Multidisciplinary management of Rett syndrome: Twenty years' experience. Genes (Basel), 14(8), 1607. https://doi.org/10.3390/genes14081607.
[18]. Bassuk, A. G. (2022). Gene therapy for Rett syndrome. Genes Brain Behav, 21(1), e12754. https://doi.org/10.1111/gbb.12754.
[19]. Sinnett, S. E., Boyle, E., Lyons, C., & Gray, S. J. (2021). Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice. Brain, 144(10), 3005-3019. https://doi.org/10.1093/brain/awab182.
Cite this article
Zhou,Y. (2025). Mecp2: An Important Role in the Pathogenesis of RETT Syndrome . Theoretical and Natural Science,90,24-31.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICMMGH 2025 Workshop: Computational Modelling in Biology and Medicine
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).